- Home
- EPM vs SPRO Comparison
EPM vs SPRO Comparison
Compare EPM & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPM
- SPRO
- Stock Information
- Founded
- EPM 2003
- SPRO 2013
- Country
- EPM United States
- SPRO United States
- Employees
- EPM N/A
- SPRO N/A
- Industry
- EPM Oil & Gas Production
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- EPM Energy
- SPRO Health Care
- Exchange
- EPM Nasdaq
- SPRO Nasdaq
- Market Cap
- EPM 154.4M
- SPRO 136.7M
- IPO Year
- EPM 1996
- SPRO 2017
- Fundamental
- Price
- EPM $3.76
- SPRO $2.27
- Analyst Decision
- EPM Hold
- SPRO Buy
- Analyst Count
- EPM 1
- SPRO 2
- Target Price
- EPM $4.50
- SPRO $5.00
- AVG Volume (30 Days)
- EPM 361.2K
- SPRO 564.9K
- Earning Date
- EPM 11-11-2025
- SPRO 11-13-2025
- Dividend Yield
- EPM 12.44%
- SPRO N/A
- EPS Growth
- EPM N/A
- SPRO N/A
- EPS
- EPM N/A
- SPRO N/A
- Revenue
- EPM $85,232,000.00
- SPRO $40,549,000.00
- Revenue This Year
- EPM N/A
- SPRO N/A
- Revenue Next Year
- EPM $1.13
- SPRO N/A
- P/E Ratio
- EPM N/A
- SPRO N/A
- Revenue Growth
- EPM N/A
- SPRO N/A
- 52 Week Low
- EPM $3.86
- SPRO $0.51
- 52 Week High
- EPM $6.14
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- EPM 20.69
- SPRO 44.31
- Support Level
- EPM $4.35
- SPRO $2.33
- Resistance Level
- EPM $4.60
- SPRO $2.57
- Average True Range (ATR)
- EPM 0.13
- SPRO 0.15
- MACD
- EPM -0.05
- SPRO -0.03
- Stochastic Oscillator
- EPM 5.06
- SPRO 2.00
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.